Portal de Periódicos da CAPES

Carta Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis

2016; European Respiratory Society; Volume: 48; Issue: 5 Linguagem: Inglês

10.1183/13993003.01249-2016

1399-3003

Giovanni Sotgiu, Simon Tiberi, Lia D’Ambrosio, Rosella Centis, Jan‐Willem C. Alffenaar, José A. Caminero, Marcos Abdo Arbex, Valentina Alarcon Guizado, Alena Aleksa, Simone Dore, Mina Gaga, Gina Gualano, Heinke Kunst, Marie-Christine Payen, Aurora Jazmín Roby Arias, Alena Skrahina, Ivan Solovič, Giorgia Sulis, Marina Tadolini, Alimuddin Zumla, Giovanni Battista Migliori,

Mycobacterium research and diagnosis

Multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are growing clinical and public health concerns, with an estimated worldwide incidence and mortality of 480 000 and 190 000 cases, respectively (2014) [1]. The World Health Organization (WHO) End TB Strategy reiterates the MDR-/XDR-TB threat and the solutions to control the epidemic [2]. Unfortunately, large proportions of patients with resistant TB do not have access to adequate diagnostics and treatment yet, while treatment success rates remain suboptimal (as demonstrated in the largest retrospective cohort of MDR-TB patients, i.e. , TB caused by Mycobacterium tuberculosis isolates resistant to at least isoniazid and rifampicin) and decrease further with resistance patterns beyond XDR-TB [3]. Evaluation of drug resistances is needed to identify candidates for the shorter regimen in MDR-TB hot spots The authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions and policies of their institutions. All authors contributed to the conception of the study, data analysis, interpretation of the results, drafting of the manuscript and approval of the final version. Members of the International Carbapenem Study Group: M. Abdo Arbex (Brazil), O.W. Akkerman (The Netherlands), E. Alarcon Arrascue (Peru), V. Alarcon Guizado (Peru), A. Aleksa (Belarus), J.W. Alffenaar (The Netherlands), J. Artsukevich (Belarus), V. Avchynka (Belarus), J.A. Caminero (Spain), R. Centis (Italy), L. D'Ambrosio (Italy), S. De Lorenzo (Italy), S. Dore (Italy), M. Gaga (Greece), G. Gualano (Italy), A.J. Roby Arias (Ecuador), E.H. Bonini (Brazil), F.A. Chong Marín (Ecuador), G. de Vries (The Netherlands), S. Dore (Italy), H. Kunst (UK), A. Matteelli (Italy), G.B. Migliori (Italy), C. Moschos (Greece), F. Palmieri (Italy), A. Papavasileiou (Greece), M.C. Payen (Belgium), A. Piana (Italy), A. Scardigli (France), A. Skrahina (Belarus), I. Solovic (Slovakia), G. Sotgiu (Italy), A. Spanevello (Italy), G. Sulis (Italy), M. Tadolini (Italy), S. Tiberi (UK), D. Vargas Vasquez (Peru), P. Viggiani (Italy), V. White (UK), A. Zumla (UK).